Discovering biomarkers for antidepressant response:protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

Article English OPEN
Lam, Raymond W. ; Milev, Roumen ; Rotzinger, Susan ; Andreazza, Ana C. ; Blier, Pierre ; Brenner, Colleen ; Daskalakis, Zafiris J. ; Dharsee, Moyez ; Downar, Jonathan ; Evans, Kenneth R. ; Farzan, Faranak ; Foster, Jane A. ; Frey, Benicio N. ; Geraci, Joseph ; Giacobbe, Peter ; Feilotter, Harriet E. ; Hall, Geoffrey B. ; Harkness, Kate L. ; Hassel, Stefanie ; Ismail, Zahinoor ; Leri, Francesco ; Liotti, Mario ; MacQueen, Glenda M. ; McAndrews, Mary Pat ; Minuzzi, Luciano ; Müller, Daniel J. ; Parikh, Sagar V. ; Placenza, Franca M. ; Quilty, Lena C. ; Ravindran, Arun V. ... view all 38 authors (2016)

Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. Methods: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. Discussion: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. Trial registration: identifier NCT01655706. Registered July 27, 2012.
  • References (67)
    67 references, page 1 of 7

    1. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, Whiteford HA. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One. 2013;8(7):e69637.

    2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800.

    3. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334-41.

    4. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS. Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health. Grand challenges in global mental health. Nature. 2011;475:27-30.

    5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.

    6. Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976-89.

    7. Stuss DT. The Ontario Brain Institute: completing the circle. Can J Neurol Sci. 2014;41(6):683-93.

    8. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22-33. quiz 34-57.

    9. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(16):10-7.

    10. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy J Affect Disord. 2009;117(1):S26-43.

  • Related Research Results (2)
  • Similar Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark